Popular Articles
Cellulite Cream

Prevalence Of Artemisinin Monotherapies Raising Risk Of Resistence
Almost half of all artemisinin manufacturers and malaria-endemic countries are "failing to comply" with WHO requirements to sell the treatment in combination with other drugs, which is increasing the risk that malaria parasites will develop resistance to artemsinin, Nature reports. "Of the 69 manufacturers of artemisinin monotherapies that the WHO has identified, 21 have withdrawn monotherapies, and 14 say they intend to comply with the WHO"s recommendations. But the remaining 34 have not yet disclosed their intentions," Nature writes.
generic viagra online
Animal TB "Tracker" To Speed Drug And Vaccine Studies
Johns Hopkins researchers have developed a novel way to monitor in real time the behavior of the TB bacterium in mouse lungs noninvasively pinpointing the exact location of Mycobacterium tuberculosis. The new monitoring system is expected to speed up what is currently a slow and cumbersome process to test the safety and efficacy of various TB drug regimens and vaccines in animals. Plans are already under way for developing a similar system to monitor TB disease in humans.
News of the day
Successful Neurosurgery With Transcranial MR-guided High-Intensity Focused Ultrasound
The Magnetic Resonance Center of the University Children"s Hospital Zurich has achieved a world first break through in MR-guided, non-invasive neurosurgery. Ten patients have been successfully treated by means of transcranial high-intensity focused ultrasound. This fully non-invasive procedure opens new horizons for neurosurgery and the treatment of different neurological brain disorders.
Cardiovascular

A Compound Found In The Sea Provides Promising New Treatment For Neuropathic Pain

A paper just published in the British Journal of Pharmacology reports that a compound originally isolated from a soft coral (Capnella imbricate) could lead scientists to develop a new variety of treatments for neuropathic pain. This composite is collected at Green Island off Taiwan and could be a new option for treatment. Neuropathic pain is chronic and occasionally follows damage to the nervous system. Presently this type of pain is very poorly controlled by the usual analgesics: aspirin like drugs (NSAIDS) or even opioids like morphine. New treatments are urgently required. Inflammation in the nervous system is a major contributing factor for this condition according to recent research. Microglia and astrocytes are supporting cells that surround the nerve cells. They are activated by inflammation. These activated cells release compounds called cytokines that can stimulate nerves carrying pain sensation (nociceptive pathways). This causes the person to experience from mildly uncomfortable stimuli to very painful (hyperalgesia), or stimuli that would normally induce no discomfort at all or aching (allodynia). As a result, cold drafts or lightly brushing the skin can produce intense pain. This severely affects the person"s quality of life. There is a range of treatments that give some relief to some patients. Nearly all were found empirically and with many other effects. For example, Amitriptyline is an anti depressant currently used for urinary incontinence and it has given relief in neuropathic pain. Similarly, gabapentin and pentagabalin are two drugs designed for treating epilepsy and they have also proved helpful for some sufferers. On the other hand, a lot of patients do not respond to these presently existing drugs. Dr Zhi-Hong Wen, played an important role in a research study searching for new compounds that have potential for use in pain relief. He says: "New, effective and safe painkillers are urgently needed for patients with neuropathic pain." Dr Wen and his collaborators work at the Department of Marine Biotechnology and Res, at the National Sun Yat-Sen University in Taiwan. Capnellene is a chemical that was originally isolated in 1974. However, it is only recently that scientists have started to understand its potential. Interestingly, the structure of capnellene is extremely different from pain-relieving drugs presently used. Original experiments indicated that it could possibly have pain-relieving properties. Dr Wen, together with Yen-Hsuan Jean MD, PhD and other colleagues tested capnellene. They also studied a second very similar compound. They used isolated microglial cells and experimental models of the condition in rats. Their findings confirmed that the compounds considerably reduced pain-related activities in isolated microglia. In addition, these compounds also significantly reversed hyperalgesic behaviour in the experimental rats. Dr Wen says: "To provide better quality of life, we need new drugs that can act rapidly and have specific functions with low side effects. Moreover, we need better management for chronic pain conditions." He comments: "Today there are few pharmacological agents that can help people suffering from neuropathic pain, but we believe that these marine-derived compounds could lead to the development of a new range of drugs of great potential." "Capnellene, a natural marine compound derived from soft coral, attenuates chronic constriction injury-induced neuropathic pain in rats." Yen-Hsuan Jean, WuFu Chen, Chun-Sung Sung, Chan-Yih Duh, Shi-Ying Huang, Chan-Shing Lin, Ming-Hon Tai, Shun-Fen Tzeng and Zhi-Hong Wen doi:10.1111/j.1476-5381.2009.00323.x British Journal of Pharmacology Written by Stephanie Brunner (B.A.) Copyright: Medical News Today Not to be reproduced without permission of Medical News Today


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):